Resmed (RMD) FY2016 results: revenue $1.8 billion, up 9.5% on the year
Resmed Inc. (RMD) reported revenue of $1.8 billion for fiscal 2016, the year ended 30 June 2016, up 9.5% on the year before. Net income was $352 million, down 0.1%, and diluted earnings per share $2.49. The figures are the company's own, from the 10-K it filed with the SEC on 5 August 2016.
Revenue
$1.8 billion
+9.5% on the year
FY2009FY2016
Operating margin
23.3%
24.4% a year earlier
FY2009FY2016
Net income
$352 million
-0.1% on the year
FY2009FY2016
Diluted EPS
$2.49
+0.8% on the year
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
1,839
1,679
1,555
+9.5%
Cost of revenue
772
668
565
+15.7%
Gross profit
1,066
1,011
990
+5.4%
Gross margin
58.0%
60.2%
63.7%
Research and development
119
115
118
+3.3%
Selling, general and administrative
488
479
450
+2.0%
Operating income
429
409
405
+4.8%
Operating margin
23.3%
24.4%
26.1%
Interest expense
11.2
5.8
6.1
+93.9%
Pre-tax income
440
436
431
+0.8%
Income tax
87.2
83.0
85.8
+5.0%
Effective tax rate
19.8%
19.0%
19.9%
Net income
352
353
345
-0.1%
Net margin
19.2%
21.0%
22.2%
Diluted EPS
$2.49
$2.47
$2.39
+0.8%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
548
383
391
+43.0%
Capital expenditure
58.5
62.5
72.7
-6.3%
Free cash flow
489
321
319
+52.6%
Free cash flow margin
26.6%
19.1%
20.5%
Cash from investing
-1,126
n/a
n/a
Cash from financing
613
n/a
n/a
Depreciation and amortisation
86.8
73.1
73.5
+18.9%
Share-based compensation
46.4
47.9
43.5
-3.0%
Buybacks
102
160
202
-36.3%
Dividends paid
168
157
142
+6.9%
Dividend per share
$1.20
$1.12
$1.00
+7.1%
Diluted shares, weighted
142m
143m
144m
-0.7%
Shares outstanding at period end
141m
140m
140m
+0.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
1,695
1,587
1,758
+6.8%
Debt
1,175
301
301
+290.9%
Other liabilities
389
296
302
+31.3%
Total liabilities and equity
3,259
2,184
2,361
+49.2%
Fixed assets
384
388
434
-0.9%
Goodwill
1,059
264
289
+300.8%
Intangible assets
300
47.1
45.2
+536.0%
Cash and equivalents
731
717
906
+2.0%
Receivables
382
363
360
+5.4%
Inventory
224
247
165
-9.1%
Other assets
178
158
161
+12.1%
Total assets
3,259
2,184
2,361
+49.2%
10-K for the year ended 30 June 2016, filed 5 August 2016: the filing.